Seattle Genetics, Inc. (NASDAQ:SGEN) EVP Darren S. Cline sold 4,784 shares of the business’s stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $74.23, for a total transaction of $355,116.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

SGEN stock opened at $76.86 on Friday. Seattle Genetics, Inc. has a 1 year low of $47.75 and a 1 year high of $77.00.

Seattle Genetics (NASDAQ:SGEN) last released its quarterly earnings data on Thursday, July 26th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.81. The business had revenue of $170.20 million during the quarter, compared to analysts’ expectations of $141.07 million. Seattle Genetics had a negative net margin of 7.75% and a negative return on equity of 21.01%. The firm’s quarterly revenue was up 57.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.39) EPS. research analysts expect that Seattle Genetics, Inc. will post -1.41 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of SGEN. Baker BROS. Advisors LP grew its holdings in Seattle Genetics by 3.0% during the 2nd quarter. Baker BROS. Advisors LP now owns 51,046,060 shares of the biotechnology company’s stock worth $3,388,948,000 after acquiring an additional 1,470,651 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in Seattle Genetics during the 2nd quarter worth approximately $83,840,000. BlackRock Inc. grew its holdings in Seattle Genetics by 9.5% during the 1st quarter. BlackRock Inc. now owns 8,492,963 shares of the biotechnology company’s stock worth $444,521,000 after acquiring an additional 736,469 shares during the last quarter. Eagle Asset Management Inc. bought a new stake in Seattle Genetics during the 2nd quarter worth approximately $37,747,000. Finally, Carillon Tower Advisers Inc. bought a new stake in Seattle Genetics during the 2nd quarter worth approximately $26,267,000.

Several equities analysts have recently commented on SGEN shares. Zacks Investment Research upgraded shares of Seattle Genetics from a “hold” rating to a “buy” rating and set a $85.00 target price for the company in a research report on Thursday, August 23rd. HC Wainwright reiterated a “buy” rating on shares of Seattle Genetics in a research report on Tuesday, June 5th. TheStreet upgraded shares of Seattle Genetics from a “d+” rating to a “c-” rating in a research report on Thursday, June 28th. BidaskClub upgraded shares of Seattle Genetics from a “hold” rating to a “buy” rating in a research report on Wednesday, August 15th. Finally, Barclays reiterated a “buy” rating and set a $80.00 price objective on shares of Seattle Genetics in a research report on Friday, July 27th. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $71.64.

About Seattle Genetics

Seattle Genetics, Inc, a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.

Recommended Story: Technical Analysis

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.